Taconic Biosciences News

Taconic Biosciences News is your source for current and relevant news on how animal models are being used to drive drug discovery. Use the links below to explore exciting announcements from Taconic via Press Releases, Taconic’s press coverage in Publications and Media, and critical scientific insights within Industry News.

Natural born KILLERS - how natural killer cell therapy will transform immunotherapy

Taconic Biosciences' Dr. Azusa Tanaka and Dr. Michael Seiler penned this Drug Discovery World article regarding NK (natural killer) cell therapy and how this will transform immunotherapy: "Regulatory approval of CAR-T cell therapies in 2017 placed the spotlight on immunotherapy approaches that use live cells to attack tumours - a major shift in oncology treatment. Yet even this groundbreaking therapy has limitations, such as when patients already...

Read More

Taconic Biosciences Licenses Easi-CRISPR Technology from the University of Nebraska

Rensselaer, NY — April 20, 2018 - Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, has been granted a license to the Easi-CRISPR technology from the University of Nebraska. Easi-CRISPR was developed in the laboratories of Drs. Masato Ohtsuka (Tokai University in Japan), and Channabasavaiah Gurumurthy (University of Nebraska). The terms of the agreement include a world-wide, non-exclusive license to the...

Read More

Taconic Biosciences Launches New Inflammatory Bowel Disease Models

Rensselaer, NY — April 19, 2018 - Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, announces the launch of several new inflammatory bowel disease (IBD) animal models. As a fully-licensed provider of CRISPR/Cas9 gene editing technology, Taconic scientists knocked out the mouse Il10 gene to generate a spontaneous colitis mouse models. The new knockout models were created on Taconic's B6 (C57BL/6NTac)...

Read More

GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway

In Scientific Reports volume 8, Article number: 5750(2018), S Kelinsimon et al. from Universitätsmedizin, Berlin, Germany analyzed modulatory effects on the cell cycle by viscumTT in three osteosarcoma cell lines in vivo with eight-week-old female CIEA NOG mouse® (NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac) from Taconic Biosciences. In several pediatric tumor entities, ViscumTT has shown synergistic induction of apoptosis. In this paper, they report reduction of tumor volume and confirmed the...

Read More

GEN Roundup: Animal Models Primed for Evolutionary Burst

Dr. Michael Seiler of Taconic Biosciences discusses animal models that will advance research, drug testing, and clinical studies in this Genetic Engineering & Biotechnology News article: "Dramatic environmental change imposes new challenges. It also creates new opportunities, opening niches and potentially triggering a period of adaptive radiation, a rapid diversification of new forms. Although adaptive radiation is usually understood to be a process that occurs in nature,...

Read More

The silent microbiome crisis

The Washington Post focuses on the concern of many scientists that "Microbes are disappearing from our bodies," and discusses potential contributing factors: "It is a crisis some scientists believe has similar proportions to climate change, but it gets much less coverage: Microbes are disappearing from our bodies. You may have heard that trillions of microbes -- bacteria, fungi, viruses, protists -- live on every surface of your...

Read More

Taconic Biosciences Announces the Formation of Scientific Advisory Board

Rensselaer, NY — February 21, 2018 - Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced the formation of its Scientific Advisory Board (SAB) with the initial appointments of J. Victor Garcia, PhD, Andrew Goodman, PhD, and David Hill, PhD. The SAB will collaborate with Taconic's management in providing scientific insight and guidance on the evolution of the company's product and service...

Read More

Taconic Biosciences has new headquarters

Troy Record speaks with Taconic Biosciences CEO Bob Rosenthal about the rationale behind moving their headquarters: "Community leaders welcomed lab animal company Taconic Biosciences to its new local headquarters on Friday at a ribbon cutting ceremony. Founded in 1949, Taconic Biosciences is a breeder and supplier of laboratory animals, producing selectively bred and genetically engineered mice and rats for research use." Read the complete article at: Troyrecord.co...

Read More

Celebrating new headquarters

Times Union reports on Taconic Biosciences' ribbon cutting ceremony for the new Corporate Headquarters: "The Rensselaer County Regional Chamber of Commerce held a ribbon-cutting ceremony on Friday for Taconic Biosciences at its new headquarters office in the Cancer Research Center building at the University at Albany Health Sciences Campus in East Greenbush. Rensselaer County Executive Steve McLaughlin attended the ceremony along with Taconic CEO Robert J. Rosenthal...

Read More

Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice

CIEA's hIL-6 NOG is central in this study which "established a novel humanized transgenic (Tg) mouse strain, human interleukin (hIL)-6-expressing NOG mice (NOG-hIL-6 transgenic mice)." Taconic Biosciences is the only provider of hIL-6 NOG in EU and US: "The tumor microenvironment contains unique immune cells, termed myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) that suppress host anti-tumor immunity and promote tumor angiogenesis and metastasis. Although these...

Read More